Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study
Title:
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study
Author:
Swain, Sandra M Kim, Sung-Bae Cortés, Javier Ro, Jungsil Semiglazov, Vladimir Campone, Mario Ciruelos, Eva Ferrero, Jean-Marc Schneeweiss, Andreas Knott, Adam Clark, Emma Ross, Graham Benyunes, Mark C Baselga, José